Genitourinary Cancers | Specialty

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

July 23rd 2020

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

July 23rd 2020

UGN-102 Emerges As Potential Surgical Alternative for Low-Grade, Intermediate-Risk NMIBC

July 18th 2020

Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

Cytoreductive Nephrectomy Retains Role in mRCC in the Immune Checkpoint Inhibitor Era

July 13th 2020

Ziad Bakouny, MD, MSc, discusses the controversy behind the use of cytoreductive nephrectomy in metastatic renal cell carcinoma, factors to consider when selecting patients for this approach, and ongoing trials examining remaining questions in the field.

Rini Reviews Key ASCO 2020 Highlights in Genitourinary Cancers

July 13th 2020

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

Survey Indicates Urgent Need For COVID-19 Testing in Vulnerable Patients With Kidney Cancer

July 9th 2020

Only a small percentage of patients with kidney cancer who are considered to be particularly vulnerable to COVID-19 have actually been tested for infection.

Long-Term KEYNOTE-426 Data Support Pembrolizumab/Axitinib as Frontline Standard in Advanced RCC

July 9th 2020

Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from the phase 3 KEYNOTE-426 trial.

Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

MK-6482 Showcases Promising Clinical Activity in VHL Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, on the favorable efficacy and tolerability of MK-6482 in patients with Von Hippel-Lindau disease–associated renal cell carcinoma.

FDA Approves Avelumab as Frontline Maintenance in Metastatic Urothelial Carcinoma

July 1st 2020

The FDA has approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy.

Dr. McKay on the Design of the PDIGREE Trial in Advanced RCC

June 25th 2020

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder Cancer

June 25th 2020

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

June 25th 2020

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Investigators Strive to Refine Paradigm for Penile Cancer Treatment

June 24th 2020

Investigators are using a novel clinical trial design to test multiple treatment strategies in an effort to define the standard of care in squamous cell carcinoma of the penis.

Dr. Pal on the Background of the COSMIC-021 Trial in ​Urothelial Cancer

June 24th 2020

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Dr Agarwal on the Rationale for ​Novel Combination​ ​Therapies in ​mCRPC

June 24th 2020

Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer​.

Enfortumab Vedotin Demonstrates Additional Mechanisms of Action in UC Models

June 23rd 2020

In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.